Skip to content

Cryoanalgesia to Prevent Acute and Chronic Pain Following Surgery: A Randomized, Double-Masked, Sham-Controlled Study

Cryoanalgesia to Prevent Acute and Chronic Pain Following Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03578237
Enrollment
99
Registered
2018-07-06
Start date
2018-08-25
Completion date
2022-11-25
Last updated
2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Arthropathy, Lower Limb Amputation Above Knee, Lower Limb Amputation Below Knee, Mastectomy, Rotator Cuff Repair, Shoulder Arthroplasty, Skin Grafting, Upper Limb Amputation Above Elbow, Upper Limb Amputation Below Elbow, Video-Assisted Thoracoscopic Surgery (VATS)

Brief summary

The ultimate objective of the proposed line of research is to determine if cryoanalgesia is an effective adjunctive treatment for pain in the period immediately following various painful surgical procedures; and, if this analgesic modality decreases the risk of persistent postoperative pain, or chronic pain. The objective of the proposed pilot study is to optimize the protocol and collect data to power subsequent, definitive clinical trials. Specific Aim 1: To determine if, compared with current and customary analgesia, the addition of cryoanalgesia decreases the incidence and severity of post-surgical pain. Hypothesis 1a (primary): The severity of surgically-related pain will be significantly decreased on postoperative day 2 with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Hypothesis 1b: The incidence of chronic pain will be significantly decreased one year following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Hypothesis 1c: The severity of chronic pain will be significantly decreased one year following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Specific Aim 2: To determine if, compared with current and customary analgesia, the addition of cryoanalgesia improves postoperative functioning. Hypothesis 2a: Following primary unilateral knee and shoulder arthroplasty as well as rotator cuff repair, joint range of motion will be significantly increased within the year following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Hypothesis 2b: Following video-assisted thoracoscopic surgery, inspiratory spirometry will be improved within the month following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment.

Detailed description

Subjects will be individuals undergoing unilateral or bilateral mastectomy; upper or lower limb amputation; primary, unilateral total knee or shoulder arthroplasty; primary, unilateral rotator cuff repair; video-assisted thoracoscopic surgery; and burn-related skin grafting of the lateral thigh. Those who consent to participate in this study will have standard preoperative peripheral nerve blocks administered and catheters inserted: paravertebral blocks or a fascial plane block (e.g., erector spinae plane block) for mastectomy, femoral/sciatic for lower limb amputation, and brachial plexus (or terminal nerves) for upper limb amputation; femoral or adductor canal for total knee arthroplasty; interscalene for shoulder arthroplasty or rotator cuff repair; thoracic epidural for video-assisted thoracoscopic surgery (VATS); and lateral femoral cutaneous nerve for skin grafting of the lateral thigh. Treatment group assignment (randomization). Subjects with successfully-administered peripheral nerve blocks (defined by sensory changes in the appropriate nerve distribution) will be allocated to one of two possible treatments: 1. cryoneurolysis 2. sham cryoneurolysis (placebo control) Randomization will be stratified by surgery type (e.g., mastectomy, upper limb amputation, and lower limb amputation). Computer-generated randomization lists will be used to create sealed, opaque randomization envelopes with the treatment group assignment enclosed in each envelope labeled with the randomization number. The specific nerves targeted will depend on the surgical site: intercostal nervesblocks (4 levels depending on the specific surgical approach) for mastectomy; femoral/sciatic for lower limb amputation, and brachial plexus (or terminal nerves) for upper limb amputation; infrapatellar branch of the saphenous nerve for knee arthroplasty; suprascapular nerve for shoulder surgery; intercostal nerves for VATS procedures, and the lateral femoral cutaneous nerve for skin grafting of the lateral thigh. The cryoneurolysis sites will be cleansed with chlorhexidine gluconate and isopropyl alcohol. Using the optimal ultrasound transducer for the specific anatomic location and subject anatomy (linear vs curvilinear array), the target nerves will be identified in a transverse cross-sectional (short axis) view. We initially used a hand-held cryoneurolysis machine (Iovera, Myoscience, Redwood City, CA; prior to merger with Pacira Pharmaceuticals). For subjects randomized to sham, we inserted the angiocatheters just through the skin and subsequently place the probe through the angiocatheter, but not deeper than immediately subcutaneous (lidocaine 2% will be administered, as needed, to anesthetize the angiocatheter track). We simulated a cryo treatment but did not actually deliver gas to the probe. Therefore, there was no temperature change. However, since all subjects had a paravertebral block in place, and intercostal cryoneurolysis approach was via the subjects' back outside of their line of vision, subjects were unable to sense much besides the pressure of the angiocatheter insertion and remained masked to treatment group. For subjects randomized to receive cryoneurolysis, the same procedure was used, only the angiocatheters inserted deeper towards the intercostal nerves, the probes situated adjacent to the intercostal nerves, and active gas passed through the probe resulting in cryoneurolysis of the target nerves. When it became available, the hand-held device was replaced by a console cryoneurolysis device. Cryoneurolysis probes are available for a console neurolysis device (PainBlocker, Epimed, Farmers Branch, Texas) that either (1) pass nitrous oxide to the tip inducing freezing temperatures; or, (2) vent the nitrous oxide at the base of the probe so that no gas reaches the probe tip, resulting in no temperature change. Importantly, these probes are indistinguishable in appearance, and therefore treating physicians, subjects, and all clinical staff will be masked to treatment group assignment \[only the treating physician/investigator performing the cryoneurolysis with be unmasked\]. An angiocatheter/introducer may be inserted beneath the ultrasound transducer and directed until the probe tip is immediately adjacent to the target nerve (lidocaine 2% will be administered, as needed, to anesthetize the angiocatheter track). The angiocatheter needle will be removed, leaving the angiocatheter through which the appropriate Epimed probe will be inserted until it is adjacent to the target nerve. The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change. The process will be repeated with the same treatment probe for any additional nerves (e.g., all nerves will receive either active cryoneurolysis or sham/placebo, and not a mix of the two possible treatments). Statistical Analysis. The limb amputation, total knee and shoulder arthroplasty, rotator cuff repair, VATS, and skin grafting subjects will be included in pilot studies to help power a future clinical trials, so the investigators will enroll a convenience sample and not have a pre-determined primary endpoint or statistical plan. However, the end points of most interest will be average pain score on postoperative day 2 for shoulder arthroplasty and skin grafting subjects, range-of-motion at 6 weeks for the rotator cuff repairs, range-of-motion for knee arthroplasty, and FEV1 for the VATS procedures. For the subjects having mastectomy, the investigators will power this study for an acute pain end point which will provide conclusive results for that end point; but, the data will also be used to help power a subsequent large, multicenter clinical trial for a chronic pain-related end point (which will require far more subjects than the investigators will enroll for the current study). For the mastectomy subjects, sample size calculations are centered around the hypothesis that cryoneurolysis decreases the incidence and severity of post-mastectomy pain in the week following surgery. To this end, the primary outcome is the average NRS (as administered as part of the Brief Pain Inventory) queried on the afternoon of postoperative day 2. The difference in the distribution of NRS between groups will be assessed using the Mann-Whitney U test. The investigators approximate power using the two-sample t-test. Assuming a standard deviation of 2.25 NRS points, and minimum clinically meaningful difference of 2 NRS points, n=30 patients per group provide 86% power with two-sided alpha=5%. The t-test approximation was confirmed by simulating integer valued NRS scores in the range 0 to 10. One group was simulated by rounding normally distributed data with mean 1.5 and standard deviation 2.5 (resulting in median of 2 and interquartile range 0 to 3); and the other with mean 3.5 and standard deviation 2.5 (resulting in median of 4 and interquartile range 1 to 5). Note these resulting summary statistics are consistent with Ilfeld et al (2014). When 10,000 trials were simulated under these assumptions, the Mann-Whitney U test provided 89.5% power, and Type I error was maintained at 4.85%. Differences between groups in demographic variables and secondary endpoints will be assessed with the Mann-Whitney U test for continuous or ordinal data, and Fisher's Exact test for categorical data. Box-and-whisker plots will be used to visualize distributions by group. R version 3.4.4 (R-project.org) was used for sample size calculations and simulations; and the most recent version of R will be used at the time of analysis.

Interventions

DEVICECryoneurolysis (active)

Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature

DEVICESham cryoneurolysis procedure

Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe. Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature

Sponsors

Epimed International
CollaboratorINDUSTRY
Pacira Pharmaceuticals, Inc
CollaboratorINDUSTRY
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Only the investigator/physician applying the cryoneurolysis will be aware of the treatment group assignment.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. adult patients of at least 18 years of age 2. scheduled for a primary, unilateral total knee or shoulder arthroplasty, primary unilateral rotator cuff repair, VATS procedure, skin grafting of the lateral thigh, unilateral or bilateral mastectomy, or limb amputation distal to the femoral/humeral head and including at least one metatarsal/metacarpal bone 3. single-injection or continuous peripheral nerve blocks block or epidural infusion planned for perioperative analgesia 4. accepting of a cryoneurolysis procedure

Exclusion criteria

1. chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use \> 4 weeks) 2. pregnancy 3. incarceration 4. inability to communicate with the investigators 5. morbid obesity (body mass index \> 40 kg/m2) 6. possessing any contraindication specific to cryoneurolysis such as a localized infection at the treatment site, cryoglobulinemia, cold urticaria and Reynaud's Syndrome

Design outcomes

Primary

MeasureTime frameDescription
Average Pain (Mastectomy Subjects Only)afternoon of postoperative day 2Measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain

Secondary

MeasureTime frameDescription
Brief Pain Inventory (Interference Subscale)Months 1, 3, 6, and 12The Brief Pain Inventory short form (interference scale) is designed to assess pain's impact on physical and emotional functioning. It has established reliability and validity, with minimal inter-rater discordance, and is recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement. The interference domaine is comprised of 7 questions involving the degree of pain's interference on physical and emotional functioning using a 0-10 Likert scale (0 = none; 10 = complete). The scale is thus 0-70 with higher scores equivalent to more interference due to pain\>
Worst Pain Measured on the 11 Point Numeric Rating ScalePostoperative days 1, 2, 3, 4, 7, 14, and 21The subjects' perception of their worst level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain
Average Pain Measured on the 11 Point Numeric Rating ScalePostoperative days 1, 2, 3, 4, 7, 14, and 21The subjects' perception of their average level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain
Difficultly Sleeping Due to PainPostoperative days 1, 2, 3, 4, 7, 14, and 21Difficulty sleeping due to pain (binary answer: yes or no; not based on a scale or instrument). The numbers presented in the results are the number of participants in each treatment group answering YES, they DID have difficulty sleeping due to pain
Number of AwakeningsPostoperative days 1, 2, 3, 4, 7, 14, and 21Number of awakenings from sleep due to pain (simply the number of times of awakenings--not based on a scale or instrument)
NauseaPostoperative days 1, 2, 3, 4, 7, 14, and 21Nausea measured on a 0-10 scale with 0=no nausea and 10=vomiting; thus higher on the scale is worse
Analgesic ConsumptionPostoperative days 1, 2, 3, 4, 7, 14, 21, as well as months 1, 3, 6, and 12Analgesic consumption for previous 24 hours
Phantom Pain Duration [Mastectomy & Amputation]Postoperative months 1, 3, 6, and 12The average duration of phantom pain occurrences in the previous 3 days
Phantom Sensation Occurrences [Mastectomy & Amputation]Postoperative months 1, 3, 6, and 12How many times in the previous 3 days subject experienced phantom sensations (the number of times experienced--not based on a scale or instrument). This outcome differs from phantom pain occurrences in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation.
Phantom Sensation Duration [Mastectomy & Amputation]Postoperative months 1, 3, 6, and 12The average duration of phantom sensation occurrences in the previous 3 days. This outcome differs from phantom pain duration in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation.
Residual Limb or Wound Pain OccurencesPostoperative months 1, 3, 6, and 12How many times in the previous 3 days subject experienced residual limb or wound pain (the number of times experienced--not based on a scale or instrument)
Residual Limb or Wound Pain DurationPostoperative months 1, 3, 6, and 12The average duration of residual limb or wound pain occurrences in the previous 3 days
Phantom Pain Occurences [Mastectomy & Amputation]Postoperative months 1, 3, 6, and 12How many times in the previous 3 days subject experienced phantom pain (the number of times experienced--not based on a scale or instrument)

Countries

United States

Participant flow

Participants by arm

ArmCount
Treatment (Active Cryoneurolysis)
Receiving active cryoneurolysis Cryoneurolysis (active): Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
51
Sham
Receiving sham cryoneurolysis procedure Sham cryoneurolysis procedure: Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe. Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature
48
Total99

Withdrawals & dropouts

PeriodReasonFG000FG001
Postoperative Day 0 - Month 12Timepoints past 21 days were only for amputee and mastectomy subjects and not others1416

Baseline characteristics

CharacteristicTreatment (Active Cryoneurolysis)ShamTotal
Age, Continuous51.1 years
STANDARD_DEVIATION 15
52 years
STANDARD_DEVIATION 16
51.5 years
STANDARD_DEVIATION 15.4
Body Mass Index25.9 kg/m^2
STANDARD_DEVIATION 4.6
25.0 kg/m^2
STANDARD_DEVIATION 4.5
25.4 kg/m^2
STANDARD_DEVIATION 4.6
Height165.1 centimeters
STANDARD_DEVIATION 8
165.7 centimeters
STANDARD_DEVIATION 7.6
165.4 centimeters
STANDARD_DEVIATION 7.7
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
40 Participants31 Participants71 Participants
Sex: Female, Male
Male
11 Participants17 Participants28 Participants
Weight70.6 kilograms
STANDARD_DEVIATION 13.7
68.8 kilograms
STANDARD_DEVIATION 14.8
69.6 kilograms
STANDARD_DEVIATION 14.2

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 512 / 48
other
Total, other adverse events
0 / 510 / 48
serious
Total, serious adverse events
0 / 510 / 48

Outcome results

Primary

Average Pain (Mastectomy Subjects Only)

Measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain

Time frame: afternoon of postoperative day 2

ArmMeasureValue (MEDIAN)
ACTIVE CryoneurolysisAverage Pain (Mastectomy Subjects Only)0.0 score on a scale
SHAM CryoneurolysisAverage Pain (Mastectomy Subjects Only)3.0 score on a scale
Secondary

Analgesic Consumption

Analgesic consumption for previous 24 hours

Time frame: Postoperative days 1, 2, 3, 4, 7, 14, 21, as well as months 1, 3, 6, and 12

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 11.2 tablets of oxycodone (5 mg tablets)Standard Deviation 2.3
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 210.1 tablets of oxycodone (5 mg tablets)Standard Deviation 0.5
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 40.7 tablets of oxycodone (5 mg tablets)Standard Deviation 1.5
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Month 10 tablets of oxycodone (5 mg tablets)Standard Deviation 0
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 3.8 tablets of oxycodone (5 mg tablets)Standard Deviation 1.9
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Month 30 tablets of oxycodone (5 mg tablets)Standard Deviation 0
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 70.5 tablets of oxycodone (5 mg tablets)Standard Deviation 1.2
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Month 60 tablets of oxycodone (5 mg tablets)Standard Deviation 0
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 21.0 tablets of oxycodone (5 mg tablets)Standard Deviation 1.6
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Month 120 tablets of oxycodone (5 mg tablets)Standard Deviation 0
ACTIVE CryoneurolysisAnalgesic ConsumptionPostoperative Day 140.2 tablets of oxycodone (5 mg tablets)Standard Deviation 0.6
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Month 120 tablets of oxycodone (5 mg tablets)Standard Deviation 0
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 13.3 tablets of oxycodone (5 mg tablets)Standard Deviation 4.5
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 33.2 tablets of oxycodone (5 mg tablets)Standard Deviation 3.7
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 42.7 tablets of oxycodone (5 mg tablets)Standard Deviation 3.5
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 71.5 tablets of oxycodone (5 mg tablets)Standard Deviation 2.2
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 140.5 tablets of oxycodone (5 mg tablets)Standard Deviation 1.3
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 210.3 tablets of oxycodone (5 mg tablets)Standard Deviation 0.8
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Month 10 tablets of oxycodone (5 mg tablets)Standard Deviation 0
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Month 30 tablets of oxycodone (5 mg tablets)Standard Deviation 0
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Month 60 tablets of oxycodone (5 mg tablets)Standard Deviation 0
SHAM CryoneurolysisAnalgesic ConsumptionPostoperative Day 24.1 tablets of oxycodone (5 mg tablets)Standard Deviation 3.8
Secondary

Average Pain Measured on the 11 Point Numeric Rating Scale

The subjects' perception of their average level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain

Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 31.2 score on a scaleStandard Deviation 2.1
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 70.8 score on a scaleStandard Deviation 1.3
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 21.5 score on a scaleStandard Deviation 2
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 140.9 score on a scaleStandard Deviation 1.9
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 41.2 score on a scaleStandard Deviation 2
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 21.7 score on a scaleStandard Deviation 1.5
ACTIVE CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 11.5 score on a scaleStandard Deviation 1.8
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 211.6 score on a scaleStandard Deviation 1.8
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 13.2 score on a scaleStandard Deviation 2.1
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 23.3 score on a scaleStandard Deviation 1.9
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 32.8 score on a scaleStandard Deviation 1.9
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 42.4 score on a scaleStandard Deviation 1.9
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 72 score on a scaleStandard Deviation 1.9
SHAM CryoneurolysisAverage Pain Measured on the 11 Point Numeric Rating ScalePostoperative day 141.6 score on a scaleStandard Deviation 1.5
Secondary

Brief Pain Inventory (Interference Subscale)

The Brief Pain Inventory short form (interference scale) is designed to assess pain's impact on physical and emotional functioning. It has established reliability and validity, with minimal inter-rater discordance, and is recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement. The interference domaine is comprised of 7 questions involving the degree of pain's interference on physical and emotional functioning using a 0-10 Likert scale (0 = none; 10 = complete). The scale is thus 0-70 with higher scores equivalent to more interference due to pain\>

Time frame: Months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 10 units on a scaleStandard Deviation 0
ACTIVE CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 30 units on a scaleStandard Deviation 0
ACTIVE CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 60 units on a scaleStandard Deviation 0
ACTIVE CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 120 units on a scaleStandard Deviation 0
SHAM CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 120.3 units on a scaleStandard Deviation 0.9
SHAM CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 14.1 units on a scaleStandard Deviation 9.2
SHAM CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 61.1 units on a scaleStandard Deviation 2.3
SHAM CryoneurolysisBrief Pain Inventory (Interference Subscale)Month 30.6 units on a scaleStandard Deviation 2.9
Secondary

Difficultly Sleeping Due to Pain

Difficulty sleeping due to pain (binary answer: yes or no; not based on a scale or instrument). The numbers presented in the results are the number of participants in each treatment group answering YES, they DID have difficulty sleeping due to pain

Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 36 Participants
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 74 Participants
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 26 Participants
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 144 Participants
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 43 Participants
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 214 Participants
ACTIVE CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 15 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 217 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 111 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 211 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 313 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 410 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 711 Participants
SHAM CryoneurolysisDifficultly Sleeping Due to PainPostoperative day 147 Participants
Secondary

Nausea

Nausea measured on a 0-10 scale with 0=no nausea and 10=vomiting; thus higher on the scale is worse

Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisNauseaPostoperative day 1.5 units on a scaleStandard Deviation 1.5
ACTIVE CryoneurolysisNauseaPostoperative day 7.1 units on a scaleStandard Deviation 0.3
ACTIVE CryoneurolysisNauseaPostoperative day 2.1 units on a scaleStandard Deviation 0.5
ACTIVE CryoneurolysisNauseaPostoperative day 140 units on a scaleStandard Deviation 0
ACTIVE CryoneurolysisNauseaPostoperative day 4.2 units on a scaleStandard Deviation 1.1
ACTIVE CryoneurolysisNauseaPostoperative day 210 units on a scaleStandard Deviation 0
ACTIVE CryoneurolysisNauseaPostoperative day 30 units on a scaleStandard Deviation 0
SHAM CryoneurolysisNauseaPostoperative day 210 units on a scaleStandard Deviation 0
SHAM CryoneurolysisNauseaPostoperative day 1.6 units on a scaleStandard Deviation 2.1
SHAM CryoneurolysisNauseaPostoperative day 2.3 units on a scaleStandard Deviation 0.9
SHAM CryoneurolysisNauseaPostoperative day 30.3 units on a scaleStandard Deviation 1.1
SHAM CryoneurolysisNauseaPostoperative day 4.1 units on a scaleStandard Deviation 0.9
SHAM CryoneurolysisNauseaPostoperative day 7.3 units on a scaleStandard Deviation 1.7
SHAM CryoneurolysisNauseaPostoperative day 140 units on a scaleStandard Deviation 0
Secondary

Number of Awakenings

Number of awakenings from sleep due to pain (simply the number of times of awakenings--not based on a scale or instrument)

Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 3.4 AwakeningsStandard Deviation 1.2
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 7.1 AwakeningsStandard Deviation 0.4
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 2.3 AwakeningsStandard Deviation 1
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 14.3 AwakeningsStandard Deviation 1
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 4.3 AwakeningsStandard Deviation 0.9
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 21.2 AwakeningsStandard Deviation 0.9
ACTIVE CryoneurolysisNumber of AwakeningsPostoperative day 10.1 AwakeningsStandard Deviation 0.6
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 21.4 AwakeningsStandard Deviation 0.9
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 1.8 AwakeningsStandard Deviation 1.4
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 2.5 AwakeningsStandard Deviation 1
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 3.9 AwakeningsStandard Deviation 1.6
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 4.5 AwakeningsStandard Deviation 0.8
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 7.5 AwakeningsStandard Deviation 1
SHAM CryoneurolysisNumber of AwakeningsPostoperative day 14.3 AwakeningsStandard Deviation 0.6
Secondary

Phantom Pain Duration [Mastectomy & Amputation]

The average duration of phantom pain occurrences in the previous 3 days

Time frame: Postoperative months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 10 hoursStandard Deviation 0
ACTIVE CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 30 hoursStandard Deviation 0
ACTIVE CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 60 hoursStandard Deviation 0
ACTIVE CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 120 hoursStandard Deviation 0
SHAM CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 120 hoursStandard Deviation 0.2
SHAM CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 10.1 hoursStandard Deviation 0.2
SHAM CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 65.1 hoursStandard Deviation 20.1
SHAM CryoneurolysisPhantom Pain Duration [Mastectomy & Amputation]Month 30 hoursStandard Deviation 0.2
Secondary

Phantom Pain Occurences [Mastectomy & Amputation]

How many times in the previous 3 days subject experienced phantom pain (the number of times experienced--not based on a scale or instrument)

Time frame: Postoperative months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 10 OccurrencesStandard Deviation 0
ACTIVE CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 30 OccurrencesStandard Deviation 0
ACTIVE CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 60 OccurrencesStandard Deviation 0
ACTIVE CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 120 OccurrencesStandard Deviation 0
SHAM CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 120.4 OccurrencesStandard Deviation 1.2
SHAM CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 10.5 OccurrencesStandard Deviation 1.8
SHAM CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 64.0 OccurrencesStandard Deviation 1.9
SHAM CryoneurolysisPhantom Pain Occurences [Mastectomy & Amputation]Month 39.8 OccurrencesStandard Deviation 2.5
Secondary

Phantom Sensation Duration [Mastectomy & Amputation]

The average duration of phantom sensation occurrences in the previous 3 days. This outcome differs from phantom pain duration in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation.

Time frame: Postoperative months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 10 hoursStandard Deviation 0
ACTIVE CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 30 hoursStandard Deviation 0
ACTIVE CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 60 hoursStandard Deviation 0
ACTIVE CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 120 hoursStandard Deviation 0
SHAM CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 127.8 hoursStandard Deviation 26.8
SHAM CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 10 hoursStandard Deviation 0
SHAM CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 61.7 hoursStandard Deviation 8.9
SHAM CryoneurolysisPhantom Sensation Duration [Mastectomy & Amputation]Month 30.1 hoursStandard Deviation 0.3
Secondary

Phantom Sensation Occurrences [Mastectomy & Amputation]

How many times in the previous 3 days subject experienced phantom sensations (the number of times experienced--not based on a scale or instrument). This outcome differs from phantom pain occurrences in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation.

Time frame: Postoperative months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 10 incidencesStandard Deviation 0
ACTIVE CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 30 incidencesStandard Deviation 0
ACTIVE CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 60 incidencesStandard Deviation 0
ACTIVE CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 120 incidencesStandard Deviation 0
SHAM CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 1210.3 incidencesStandard Deviation 26.7
SHAM CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 10 incidencesStandard Deviation 0
SHAM CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 60.5 incidencesStandard Deviation 1.7
SHAM CryoneurolysisPhantom Sensation Occurrences [Mastectomy & Amputation]Month 31.2 incidencesStandard Deviation 3.1
Secondary

Residual Limb or Wound Pain Duration

The average duration of residual limb or wound pain occurrences in the previous 3 days

Time frame: Postoperative months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisResidual Limb or Wound Pain DurationMonth 30 hoursStandard Deviation 0
ACTIVE CryoneurolysisResidual Limb or Wound Pain DurationMonth 10.1 hoursStandard Deviation 0.3
ACTIVE CryoneurolysisResidual Limb or Wound Pain DurationMonth 60 hoursStandard Deviation 0.2
ACTIVE CryoneurolysisResidual Limb or Wound Pain DurationMonth 120 hoursStandard Deviation 0
SHAM CryoneurolysisResidual Limb or Wound Pain DurationMonth 120 hoursStandard Deviation 0.2
SHAM CryoneurolysisResidual Limb or Wound Pain DurationMonth 65.3 hoursStandard Deviation 20.1
SHAM CryoneurolysisResidual Limb or Wound Pain DurationMonth 117.6 hoursStandard Deviation 37.8
SHAM CryoneurolysisResidual Limb or Wound Pain DurationMonth 33.5 hoursStandard Deviation 18.4
Secondary

Residual Limb or Wound Pain Occurences

How many times in the previous 3 days subject experienced residual limb or wound pain (the number of times experienced--not based on a scale or instrument)

Time frame: Postoperative months 1, 3, 6, and 12

Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 10.9 OccurrencesStandard Deviation 1.6
ACTIVE CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 30 OccurrencesStandard Deviation 0
ACTIVE CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 60.1 OccurrencesStandard Deviation 0.4
ACTIVE CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 120.1 OccurrencesStandard Deviation 0.4
SHAM CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 121.1 OccurrencesStandard Deviation 3.4
SHAM CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 120 OccurrencesStandard Deviation 37.1
SHAM CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 65.3 OccurrencesStandard Deviation 18.4
SHAM CryoneurolysisResidual Limb or Wound Pain OccurencesMonth 34.4 OccurrencesStandard Deviation 18.4
Secondary

Worst Pain Measured on the 11 Point Numeric Rating Scale

The subjects' perception of their worst level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain

Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21

ArmMeasureGroupValue (MEAN)Dispersion
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 32.8 score on a scaleStandard Deviation 2.7
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 72.4 score on a scaleStandard Deviation 2.4
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 23.3 score on a scaleStandard Deviation 2.9
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 141.6 score on a scaleStandard Deviation 2.4
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 42.4 score on a scaleStandard Deviation 2.6
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 211.4 score on a scaleStandard Deviation 2.6
ACTIVE CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 13.7 score on a scaleStandard Deviation 2.5
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 213.0 score on a scaleStandard Deviation 2.5
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 15.5 score on a scaleStandard Deviation 2.4
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 25.6 score on a scaleStandard Deviation 2.7
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 35.1 score on a scaleStandard Deviation 2.8
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 44.3 score on a scaleStandard Deviation 2.7
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 73.7 score on a scaleStandard Deviation 2.4
SHAM CryoneurolysisWorst Pain Measured on the 11 Point Numeric Rating ScalePostoperative Day 143.1 score on a scaleStandard Deviation 2.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026